Clinical References

Aubin H-J et al. Varenicline versus transdermal nicotine patch for smoking cessation: results from a randomised, open-label trial. Thorax 2008; 63:717-724.

CHAMPIX Patient Information Leaflet. February 2014.

Hughes JR. New treatments for smoking cessation. CA Cancer J Clin 2000; 50:143-151.

Mills EJ et al. Comparisons of high-dose and combination nicotine replacement therapy, varenicline, and bupropion for smoking cessation: A systematic review and multiple treatment meta-analysis. Ann Med 2012; 44:588-597.

Supplementary material for Mills EJ et al. Comparisons of high dose and combination nicotine replacement therapy, varenicline and bupropion for smoking cessation: A systematic review and multiple treatment meta-analysis. Ann Med 2012; 44:588-597.

Rennard S et al. A randomized placebo-controlled trial of varenicline for smoking cessation allowing flexible quit dates. Nicotine Tob Res 2012; 14:343-350.

McEwen A et al. Manual of smoking cessation. A guide for counsellors and practitioners. 2006, Addiction Press: Blackwell Publishing.

American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders Fourth Edition Text Revision. Washington, DC: American Psychiatric Association; 2000.

Rigotti NA et al. Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease. A randomised trial. Circulation 2010; 121:221-229.

Tonstad S et al. Psychiatric adverse events in randomized, double-blind, placebo-controlled clinical trials of varenicline: a pooled analysis. Drug Saf 2010; 33:289-301.

Gonzales D et al. Varenicline, an a4ß2 nicotinic acetylcholine receptor partial agonist, vs sustained release bupropion and placebo for smoking cessation. A randomized controlled trial. JAMA 2006; 296:47-55.

Jorenby DE et al. Efficacy of varenicline, an a4ß2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation. A randomized controlled trial. JAMA 2006; 296:56-63.

Andreas S et al. Effectiveness of varenicline as an aid to smoking cessation in primary care: an observational study. Eur Addict Res 2013; 19:47-54.

Boudrez H et al. Effectiveness of varenicline as an aid to smoking cessation: results of an inter-European observational study. Curr Med Res Opin 2011; 27(4):769-775.

West R, Shiffman S. Fast Facts. Smoking cessation. Indispensable guides to clinical practice. 2004, Oxford: Health Press.

European Public Assessment Report (EPAR). CHAMPIX: Scientific discussion. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000699/WC500025254.pdf. Last accessed: April 2014.

Coe JW et al. Varenicline: An a4ß2 nicotinic receptor partial agonist for smoking cessation. J Med Chem 2005; 48:3474-3477.

West R et al. Effect of varenicline and bupropion SR on craving, nicotine withdrawal symptoms, and rewarding effects of smoking during a quit attempt. Psychopharmacology 2008; 197:371-377.

Jarvis MJ. Why people smoke. BMJ 2004; 328:277-279.

Tonstad S et al. Effect of maintenance therapy with vareniciline on smoking cessation. A randomized controlled trial. JAMA 2006; 296:64-71.

Siru R, Hulse GK, Tait RJ. Assessing motivation to quit smoking in people with mental illness: a review. Addiction 2009; 104:719-33.

Anthenelli RM, Morris C, Ramey TS et al. Effects of varenicline on smoking cessation in adults with stably treated current or past major depression. A randomised trial. Ann Intern Med 2013; 159:390–400.Anthenelli RM, Morris C, Ramey TS et al. Effects of varenicline on smoking cessation in adults with stably treated current or past major depression. A randomised trial. Ann Intern Med 2013; 159:390–400.

Gibbons RD, Mann JJ. Varenicline, smoking cessation, and neuropsychiatric adverse events Am J Psychiatry 2013; 170:1460-1467.